Due to the paucity of data and rarity of DS in IDH-inhibitors, we believe the warnings from competent authorities are justified, and treating oncologists should be mindful of the potential of DS in non-M3 AML patients. This evidence concerns the gene IDH2 and acute myeloid leukemia.